Onsite Launches Outpatient Services at Onsite Wellness House in Nashville
Onsite Wellness House brings the best of Onsite and Milestones to those in Nashville and surrounding areas while minimizing disruption...
Brain
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer’s Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
We Heart You: Recovery in Our Community Event 2024
What: We Heart You: Recovery in Our Community EventWhen: Wednesday, March 13, 12:00-5:00 PM(Welcome at 12:30 PM, Keynote speaker from...
Zeto Adds New Chief Financial Officer to Accelerate Growth
SANTA CLARA, CA / ACCESSWIRE / March 6, 2024 / Zeto, Inc., a commercial-stage medical technology company transforming EEG brain...
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,...
Nalu Medical, Inc. Closes $85 Million Series E Round
B Capital invests incremental $20M; previously raised $65M led by Novo Holdings with participation from existing investors Equity investment to...
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill assess weight loss and blood glucose...
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
TORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related...
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod...
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunctionBETHESDA,...
AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer’s
STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome...
Advocacy Groups Join Reagan-Udall Foundation and FDA for Workshop on Developing Biomarkers to Support Accelerated Approval in Rare Diseases
Workshop Presented Overwhelming Scientific Evidence to Support CSF-HS as a Primary Biomarker in Neuropathic MPS DisordersWASHINGTON, DC / ACCESSWIRE /...